Annals of Oncology 14:1791, 2003
© 2003 European Society for Medical Oncology
Letters to the Editor |
Continuously elevated cardiac troponin I in two patients with multiple myeloma and fatal cardiac amyloidosis
1 General Hospital Kufstein, Department of Internal Medicine and Oncology, Endach 27, 6330 Kufstein; 2 Department of Pathology, University of Inssbruck, Müllerstraße 44, 6020 Innsbruck, Austria
*E-mail: a.zabernigg@kufnet.at
| The first 10% of the full text of this article appears below. |
Myeloma-associated systemic amyloidosis (AL) with cardiac involvement has a poor prognosis, with a median survival of <1 year [1]. Standard therapy with oral melphalan and prednisolone is unsatisfactory, with an overall response rate for AL of 20%. The diagnosis of cardiac amyloidosis in patients with multiple myeloma is most commonly based on
Case 1
Case 2
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
R. H. Falk Diagnosis and Management of the Cardiac Amyloidoses Circulation, September 27, 2005; 112(13): 2047 - 2060. [Full Text] [PDF] |
||||
![]() |
J. Zaky, C. Caraang, R. Yu, and A. El-Bialy Elevated Troponins and the Churg-Strauss Syndrome: A Case Report Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 2005; 10(2): 131 - 136. [Abstract] [PDF] |
||||

